Brennan CW, Verhaak RG, McKenna A, et al; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
Fan QW, Cheng CK, Gustafson WC, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 2013;24(4):438-449.
Piperi C, Papavassiliou KA, Papavassiliou AG. Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells. 2019; 8(11):1398.
Fan Q, An Z, Wong RA, et al. Betacellulin drives therapy-resistance in glioblastoma. Neuro Oncol. 2020;22(4):457-469.
Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13(11):1235-1242.
Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046-1061.
Rush JS, Peterson JL, Ceresa B P. Betacellulin (BTC) biases the EGFR to dimerize with ErbB3. Mol Pharmacol. 2018;94(6):1382-1390.
Dahlhoff M, Wolf E, Schneider MR. The ABC of BTC: structural properties and biological roles of betacellulin. Semin Cell Dev Biol. 2014;28:42-48.
Gómez-Gaviro MV, Scott CE, Sesay AK, et al. Betacellulin promotes cell proliferation in the neural stem cell niche and stimulates neurogenesis. Proc Natl Acad Sci USA. 2012;109(4):1317-1322.
Ouédraogo ZG, Biau J, Kemeny JL, Morel L, Verrelle P, Chautard E. Role of STAT3 in genesis and progression of human malignant gliomas. Mol Neurobiol. 2017;54(8):5780-5797.
Tan MSY, Sandanaraj E, Chong YK, et al. A STAT3-based gene signature stratifes glioma patients for targeted therapy. Nat Commun. 2019;10(1):3601.
Makhlin I, Salinas RD, Zhang D, et al. Clinical activity of the EGFR ty-rosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma. CNS Oncol. 2019; 8(3):Cns43.
Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125.
